News and commentary from the world of gastroenterology and hepatology
— News and commentary from the world of gastroenterology and hepatology
by Ian Ingram, Managing Editor, MedPage Today
June 25, 2026
• 2 min read
In patients with inflammatory bowel disease (IBD), the use of GLP-1 receptor agonists was linked to a lower risk of colorectal cancer (CRC), according to a retrospective study presented at the American Society of Clinical Oncology Breakthrough Meeting.
News and commentary from the world of gastroenterology and hepatology
News and commentary from the world of gastroenterology and hepatology
Use of GLP-1s was associated with significantly reduced risk for hepatic complications among patients with metabolic…
Nearly 1 in 5 people with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis were prescribed a GLP-1…
Early data are promising, but GLP-1 drugs aren't yet recommended as IBD therapy
Accumulating evidence of possible benefit warrants randomized trials, experts say
